Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan

• Main Authors: Mitsunobu Otsuru (Author), Nobuhiro Yamakawa (Author), Tadaaki Kirita (Author), Shin-ichi Yamada (Author), Hiroshi Kurita (Author), Takuma Kugimoto (Author), Hiroyuki Harada (Author), Takumi Hasegawa (Author), Masaya Akashi (Author), Akinori Takeshita (Author), Narikazu Uzawa (Author), Masahiro Umeda (Author), Souichi Yanamoto (Author), Tomohiro Yamada (Author)
• Format: Book
• Published: Elsevier, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background/purpose: For unresectable recurrent/metastatic head and neck cancer, pembrolizumab alone or pembrolizumab combined with cisplatin and 5-fluorouracil is the first-line therapy, depending on the PD-L1 combined positive score (CPS). However, this is based on clinical studies of head and neck...